DADC
KPTI icon

D.A. Davidson & Co’s Karyopharm Therapeutics KPTI Stock Holding History

D.A. Davidson & Co’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,733
Closed -$431K – 1209
2021
Q1 		$431K Buy
2,733
+1,200
+78% +$253K 0.01% 846
2020
Q4 		$356K Buy
+1,533
New +$355K 0.01% 804

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

D.A. Davidson & Co's KPTI Position: Q2 2021 in Review

D.A. Davidson & Co sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 2,733 shares — an estimated $431K sold.

D.A. Davidson & Co first reported a position in KPTI in Q4 2020 and held it in 2 quarters. The position peaked at $431K in Q1 2021. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

  • D.A. Davidson & Co reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
  • D.A. Davidson & Co sold 2,733 Karyopharm Therapeutics shares in Q2 2021, an estimated $431K.
  • D.A. Davidson & Co first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 2 quarters.
  • D.A. Davidson & Co's Karyopharm Therapeutics position peaked at $431K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on D.A. Davidson & Co's 13F filing for Q2 2021, filed 10 Aug 2021.